BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Roy A, Sahoo J, Narayanan N, Merugu C, Kamalanathan S, Naik D. Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence. World J Diabetes 2021; 12(9): 1426-1441 [PMID: 34630898 DOI: 10.4239/wjd.v12.i9.1426]
URL: https://www.wjgnet.com/1948-9358/full/v12/i9/1426.htm
Number Citing Articles
1
Kayo Masuko. Glucose as a Potential Key to Fuel Inflammation in Rheumatoid ArthritisNutrients 2022; 14(11): 2349 doi: 10.3390/nu14112349
2
Maria Rosa Noliza Encarnacion, Ryota Kawai, Hiroto Kuwabiraki, Nanaka Ban, Hisako Yoshida, Ayumi Shintani, Daisuke Tsuruta, Sho Hiroyasu. Clinical characteristics and outcomes of autoimmune blistering diseases in JapanThe Journal of Dermatology 2025; 52(2): 299 doi: 10.1111/1346-8138.17518
3
H. Kang, E. B. Lee, S. Lee, T. ‐H. Go, J. Y. Lee, S. ‐H. Lee, S. A. Song, H. K. Lim, S. ‐P. Hong. Dipeptidyl peptidase‐4 inhibitors increase the risk of bullous pemphigoid in older patients with diabetes: A retrospective analysis using the Korean National Health Insurance DatabaseJournal of the European Academy of Dermatology and Venereology 2023; 37(7) doi: 10.1111/jdv.18975
4
M. Ganeva. SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORSTrakia Journal of Sciences 2023; 21(1): 54 doi: 10.15547/tjs.2023.01.009
5
Neslihan USLU, Kagan GUNGOR, Gonca TAMER, Bulent CAN. Association of Dipeptidiyl Peptidase-4 Inhibitors and Bullose Pemphigoid: A Report of Four CasesMedeniyet Medical Journal 2024; : 140 doi: 10.4274/MMJ.galenos.2024.76508
6
Grigorios Thermos, Nikolaos Katsoulas, George Vilos, Konstantinos I. Tosios. DPP4‐inhibitor‐associated oral mucous membrane pemphigoidOral Diseases 2023; 29(5): 2321 doi: 10.1111/odi.14234
7
Basma Farooq Ali, Ahmed Rahmah Abu-Raghif, Hayder Ridha-Salman, Ali Jihad Hemid Al-Athari. Vildagliptin topical ointment: an effective treatment for imiquimod-induced psoriasis in miceJournal of Molecular Histology 2025; 56(3) doi: 10.1007/s10735-025-10416-4
8
Şeyhmus Kaya, Ramazan Oğuz Yüceer, Mustafa Tosun, Reikhan Mustafaeva. The role of C4d expression in the diagnosis of bullous pemphigoid: a clinical and histopathological studyArchives of Dermatological Research 2025; 317(1) doi: 10.1007/s00403-025-04031-2
9
Yuichiro Iwamoto, Takatoshi Anno, Katsumasa Koyama, Fumiko Kawasaki, Kohei Kaku, Koichi Tomoda, Seiko Sugiyama, Yumi Aoyama, Hideaki Kaneto. Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous PemphigoidFrontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.843480
10
Jie Huang, Xinxin Liu, Yingying Wei, Xinlu Li, Shupei Gao, Lingli Dong, Xiaoquan Rao, Jixin Zhong. Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune DiseaseFrontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.830863
11
Khaled R. Alkharsah, Salma Ali Aljaroodi, Jawad Ur Rahman, Awatif N. Alnafie, Reem Al Dossary, Reem Y. Aljindan, Amani M. Alnimr, Jamal Hussen, Ahmed S. Abdel-Moneim. Low levels of soluble DPP4 among Saudis may have constituted a risk factor for MERS endemicityPLOS ONE 2022; 17(4): e0266603 doi: 10.1371/journal.pone.0266603
12
Faten Hadjkacem, Hamdi Frikha, Khouloud Boujelben, Chiraz Chaari, Emna Mnif, Abderrahmen Masmoudi, Tahia Boudawara, Hamida Turki, Mohamed Abid. Bullous Pemphigoid Associated With Dipeptidyl Peptidase-4 Inhibitors: A Case Report and Review of Current EvidenceHospital Pharmacy 2023; 58(4): 357 doi: 10.1177/00185787231151861